Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study
Lung cancer still occupies the highest incidence and mortality rate in the wordwild, and non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of all lung cancers.
- Trial name
- NCT04517526
- Testing
- pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
Lung Cancer
Salivary Biomarkers for Non-small Cell Lung Cancer Detection
The investigators plan to recruit patients for a prospective study in patients in need of evaluation for lung lesions suspicious for cancer.
- Trial name
- NCT02294578
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- PeriRx
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group
Non-Small Cell Lung Cancer
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06496490
- Testing
- TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
- Where
- 25 sites in China
- Volunteers
- 270 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and…
- Conditions
- Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06495125
- Testing
- Avutometinib, Biopsy, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
A single arm, open-label phase II is appropriate to evaluate the efficacy and safety of dose - dense combination of paclitaxel with cisplatin supported by pegfilgrastim for neo-adjuvant chemotherapy in this patient population.
- Trial name
- NCT00291850
- Testing
- Paclitaxel, Cisplatin, Pegfilgrastim
- Where
- 5 sites in Austria, Hungary and 1 more
- Volunteers
- 50 people
- Sponsor
- Central European Cooperative Oncology Group
NSCLC
Tislelizumab in Addition to BACE in Patients with NSCLC
This is a single-arm phase II trial to determine the efficacy and safety of Tislelizumab in addition to bronchial arterial chemoembolization in stage III-Ⅳ NSCLC patients who failed, refused or ineligible to receive standard…
- Trial name
- NCT05058560
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Non-small Cell Lung Cancer (NSCLC)
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1.
- Trial name
- NCT05351320
- Testing
- WX-0593 Tablets, chemotherapy, Thoracic Radiation Therapy（TRT）
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jinming Yu
Advanced Solid Tumor, Non Small Cell Lung Cancer
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
- Trial name
- NCT05532696
- Testing
- ABT-101
- Where
- 5 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Anbogen Therapeutics, Inc.
NSCLC, Stage IV
Early Response Evaluation in NSCLC Patients Treated With Immunotherapy
A pilot study with biomarker exploration.50 patients with stage IV non-small cell lung cancer (NSCLC) that are eligible for treatment with nivolumab.
- Trial name
- NCT04082988
- Testing
- 18F-FDG PET-CT
- Where
- 2 sites in Netherlands
- Volunteers
- 9 people
- Sponsor
- The Netherlands Cancer Institute
Non Small Cell Lung Cancer Metastatic
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
The goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug…
- Trial name
- NCT05117242
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 40 sites in United States, France and 7 more
- Volunteers
- 125 people
- Sponsor
- Genmab
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Non Small Cell Lung Cancer
Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer
The purpose of this study is to investigate risk factors for mediastinal lymph node metastasis in potentially operable non-small cell lung cancer in order to find indications for endoscopic mediastinal staging.
- Trial name
- NCT02991924
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- National Cancer Center, Korea
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Non-small Cell Lung Cancer, RET Fusion
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
This study is a single-arm, multicenter real-world clinical study designed to evaluate the safety and efficacy of Leucogen (a leukocyte-increasing agent) as a prophylactic treatment in patients with RET fusion-positive non-small…
- Conditions
- Non-small Cell Lung Cancer, RET Fusion, Pralsetinib
- Trial name
- NCT07418879
- Testing
- Pralsetinib, Leucogen
- Volunteers
- 25 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
This Phase II study is to explore the efficacy and toxicity of Pegylated liposomal doxorubicin and Carboplatin in patients with previously untreated non-small cell lung cancer (NSCLC) not amenable to radiotherapy or surgical…
- Trial name
- NCT01051362
- Testing
- PLD and Carboplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-Small Cell Lung Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer
- Trial name
- NCT01024062
- Testing
- Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Non-small-cell Lung Cancer
ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
The primary objective of this study is to examine if the combination regimen of ARQ 197 with erlotinib is active in subjects with locally advanced or metastatic NSCLC with activating mutation EGFR who progressed on EGFR-TKI…
- Trial name
- NCT01580735
- Testing
- ARQ 197
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lung Cancer
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268489
- Testing
- bevacizumab, pemetrexed disodium
- Where
- 248 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.